[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369644-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369644-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","hpv16-expressing-tumors-release-multiple-il1-ligands-to-orchestrate-systemic-immunosuppression-whose-disruption-enables-efficacy-of-a-therapeutic-vaccine","HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine","","HPV16-driven squamous cell tumors in cervix and skin release four IL-1 family ligands—IL-1α, IL-1β, IL-33, and IL-36β—into the circulation, biasing bone marrow granulocytic myelopoiesis and generating immunosuppressive neutrophils that populate spleens and tumors. This study links tumor-driven systemic immunosuppression to impaired T-cell responses. Targeting IL-1 family signaling with anti-IL1RAP blocks neutrophil expansion and restores antitumor activity of an otherwise ineffective HPV16 E7 peptide vaccine, further supported by anti-CTLA-4.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/hpv16-expressing-tumors-release-multiple-il1-ligands-to-orchestrate-systemic-immunosuppression-whose-disruption-enables-efficacy-of-a-therapeutic-vaccine/369644/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/hpv16-expressing-tumors-release-multiple-il1-ligands-to-orchestrate-systemic-immunosuppression-whose-disruption-enables-efficacy-of-a-therapeutic-vaccine/369644.png","ImageObject",300,407,{"name":42,"@type":43},"Rizky","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What ligands do HPV16-driven tumors release to suppress immunity?","Question",{"text":63,"@type":64},"They release IL-1α, IL-1β, IL-33, and IL-36β into the circulation, shifting bone marrow development toward immunosuppressive neutrophils.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does this tumor-driven systemic immunosuppression affect immune responses?",{"text":68,"@type":64},"It biases granulocytic myelopoiesis and expands neutrophils in spleens and tumors, which cripples T-cell development and impairs antitumor immunity.",{"name":70,"@type":61,"acceptedAnswer":71},"How can the immunosuppression be disrupted to improve vaccine efficacy?",{"text":72,"@type":64},"Using the IL-1 family coreceptor antagonist anti-IL1RAP abrogates neutrophil expansion and enables an otherwise ineffective HPV16 E7 peptide vaccine to elicit an effective antitumor response.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369644,1790732950,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","ReseaRch aRticle  \nHPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine   \nMorgane Lecointre1,2,3, Jérémy Guillot1,2,3, Rachel Marcone3,4, Dilara Ozdoganlar1,2,3, Marjorie Cayatte1,2,3,  \nElin Jaensson Gyllenbäck5, David Liberg5, Nadine Fournier3,4, Krisztian Homicsko1,2,3,6,7, and Douglas Hanahan1,2,3,8  \nIt is well-established that symptomatic cancers evade immune destruction by  \ncoalescing tumor microenvironments to suppress adaptive immunity. Additionally, mouse models of cervical and other cancers have revealed a capability of tumors to systemically induce the expansion of neutrophils that cripple T-cell development in spleen and lymph nodes, further impairing immune responses. Now we show that human papillomavirus type 16 (HPV16)–driven squamous cell tumors in the cervix and skin release into the circulatory system four immunoregulatory ligands – IL-1α, IL-1β, IL-33, and IL-36β – that bias the bone marrow toward granulocytic myelopoiesis, producing immunosuppressive neutrophils populating spleens and tumors. An IL-1 family coreceptor antagonist, anti-IL1RAP, abrogates this neutrophil expansion and complements an otherwise inefficacious HPV16 E7 peptide vaccine to elicit an effective antitumor immune response that is further sustained by anti–CTLA-4 . Evidence for similarly IL-1–driven systemic immunosuppression inhuman cervical tumors encourages evaluation of this combinatorial therapeutic strategy for treating a largely immunoevasive cancer type.  \nSIgnIfICAnCE: Cervical cancer is the fourth leading cause of cancer deaths in women worldwide. Although the disease is driven by two antigenic viral oncoproteins, therapeutic vaccines have proved ineffective, inferentially due to systemic immunosuppression. This study elucidated an actionable mechanism, whose disruption renders an oncoprotein vaccine efficacious, with translational potential.  \nintRoduction  \nThe immunobiology and immunotherapy of cancer are transcendent dimensions of basic and translational cancer research, with myriad complexities reflecting diverse regulation and dichotomous responses of the innate and adaptive immune systems. It is well-established that tumors establish multifaceted immunosuppressive microenvironments that are implicated in the variable efficacy of checkpoint inhibitors and other immunotherapies across the spectrum of human cancer types (1), involving in part innate immune cells, principally tumor-associated macrophages (TAMs) and neutrophils (TANs; refs. 1–5). Moreover, the abundance of circulating neutrophils, commonly scored as the blood neutrophil-to-lymphocyte ratio (NLR), is used clinically as a prognostic marker that is often associated with a worse prognosis for patients (6) . In addition to immunosuppressive tumor microenvironments (TME),  \n1Swiss Institute for Experimental Cancer Research (ISREC), EPFL, Lausanne, Switzerland. 2Swiss Cancer Center Leman (SCCL), Lausanne, Switzerland.  \n3Agora Translational Cancer Research Center, Lausanne, Switzerland.  \n4Bioinformatics Core Facility, Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland. 5Cantargia AB, Lund, Sweden. 6Department of Oncology, CHUV, Lausanne, Switzerland. 7Center for Personalized Oncology, CHUV, Lausanne, Switzerland. 8Ludwig Institute for Cancer Research, Lausanne, Switzerland.  \nM. Lecointre and J. Guillot contributed equally to this article.  \nCorresponding Author: Douglas Hanahan, Agora Translational Cancer Research Center, Rue du Bugnon 25A, Lausanne CH-1011, Vaud, Switzerland.  \n[E-mail: douglas.hanahan@epfl.ch](E-mail: douglas.hanahan@epfl.ch)[ ](E-mail: douglas.hanahan@epfl.ch)Cancer Discov 2025;15:1458–83  \ndoi: 10. 1158/2159-8290 . CD-25-0382  \nThis open access article is distributed under the Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.©2025 The Authors; Published by the American Associatio","cbCaiaOcvPIU0KOh","https://ap.wps.com/l/cbCaiaOcvPIU0KOh","pdf",15360324,26,"English","# SIgnIfICAnCE\n## Systemic immunosuppression mechanism\n## Translational therapeutic strategy","[{\"question\":\"What ligands do HPV16-driven tumors release to suppress immunity?\",\"answer\":\"They release IL-1α, IL-1β, IL-33, and IL-36β into the circulation, shifting bone marrow development toward immunosuppressive neutrophils.\"},{\"question\":\"How does this tumor-driven systemic immunosuppression affect immune responses?\",\"answer\":\"It biases granulocytic myelopoiesis and expands neutrophils in spleens and tumors, which cripples T-cell development and impairs antitumor immunity.\"},{\"question\":\"How can the immunosuppression be disrupted to improve vaccine efficacy?\",\"answer\":\"Using the IL-1 family coreceptor antagonist anti-IL1RAP abrogates neutrophil expansion and enables an otherwise ineffective HPV16 E7 peptide vaccine to elicit an effective antitumor response.\"}]","HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine | PDF",1790183856,66,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c86f4dfcaa3eadf10e9ec8e973f0264d.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/befeecb267652dae02e71248c5dd5cf9.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5276c86e4231efbd44a91fc6a257f4bf.webp",981,1312,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7bd68fb5aefa557b506e47b04f49638.webp",980,1311]